|
|
ZIOPHARM Oncology to Present at Rodman and Renshaw 5th Annual Global Healthcare Conference
euroinvestor.co.uk May 12, 2008
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief Executive Officer, will present at the Rodman and Renshaw 5th Annual Globa.. - Read more ... ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) announced today that Dr. Jonathan Lewis, Chief...
Newstin has read and analyzed this article for you...
What is this article about?
Which companies were mentioned in the article?
Geography:
You might be also interested in the following articles found by Newstin:
Childhood Cancer Survivors Prone to Early Heart Trouble
kxan.com 12 hrs ago 34 related
By Amanda Gardner, HealthDay Reporter FRIDAY, May 16 (HealthDay News) -- Childhood cancer survivors "have approximately a five to 10 times increased risk of having heart disease compared to their healthy siblings," said study lead author Dr. Daniel A. Mulrooney, assistant professor of pediatrics...
New Treatment Implications for Ovarian Cancer Unveiled
newswise.com 13 hrs ago
Description New research findings indicate the potential for more targeted treatment of ovarian cancer through the use of the mineral selenium in combination with the standard treatment for the disease. Newswise — New research findings from a top clinical investigator at The Cancer Institute of...
Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
redorbit.com 15 hrs ago 3 related
Posted on: Friday, 16 May 2008, 12:00 CDT SOUTH SAN FRANCISCO, Calif., May 16 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc. today announced that scientific collaborators will present results on HERmark(TM), the company's novel oncology assay, as a means to measure HER2 and predict response...
Cancer Research Group Releases Data
redorbit.com 15 hrs ago 5 related
Studies of drugs that may stop the spread of many cancers -- vaccines for brain tumors, treatments that prevent bone metastases, vitamins that may improve the chances of breast cancer patients -- will be examined by some 30,000 oncologists and scientists at the world's biggest cancer-research...